Improvement of clinical response in allergic rhinitis patients treated with an oral immunostimulating bacterial lysate: In vivo immunological effects

International Journal of Immunopathology and Pharmacology

Volumn 20, Issue 1, 2007, Pages 129-138

  Banche, G ^a   Allizond, V ^a   Mandras, N ^a   Garzaro, M ^a   Cavallo, G P ^a   Baldi, C ^b   Scutera, S ^a   Musso, T ^a   Roana, J ^a   Tullio, V ^a   Carlone, N A ^a   Cuffini, Anna Maria ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Allergic rhinitis; IFN ; IgE; IL 4; Peripheral blood mononuclear cells; Polyvalent mechanical bacterial lysate

Indexed keywords

BACTERIUM LYSATE; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOSTIMULATING AGENT; IMMUNOSTIMULATING VACCINE; INTERLEUKIN 4; PLACEBO; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; BLOOD ANALYSIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSTIMULATION; IMMUNOTHERAPY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33947719010     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200702000115     Document Type: Article

References (26)

1. Romagnani S. 1997. Atopic allergy and other hypersensitivities interactions between genetic susceptibility innocuous and/or microbial antigens and the immune system. Curr. Opin. Immunol. 9:773.
2. Skoner D.P. 2001. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J. Allergy Clin. Immunol. 108:S2.
3. Rhee C., L. Libet, D. Chisholm, K. Takabayashi, S. Baird, T.D. Bigby, C. Hee Lee, A.A. Horner and E. Raz. 2004. Allergen-indipendent immunostimulatory sequence oligodeoxynucleotide therapy attenuates experimental allergic rhinitis. Immunology 113:106.
4. Tricarico D., A. Varricchio, S. D'Ambrosio, E. Ascione and G. Motta. 2004. Prevention of recurrent upper respiratory tract infections in a community of cloistered nuns using a new immunostimulating bacterial lysate. Arzneim. Forsch. Drug Res. 54:57.
5. Rossi S. and R. Tazza. 2004. Efficacy and safety of a new immunostimulating bacterial lysate in the prophylaxis of acute lower respiratory tract infections. Arzneim.-Forsch. Drug Res. 54:50.
6. Berber A.C. and B.E. Del-Rio Navarro. 1996. Use of Broncho-Vaxom in private practice: Phase IV trial in 587 children. Clin. Ther. 18:1068.
7. Gutierrez-Tarango M.D. and A. Berber. 2001. Safety and efficacy of two courses of OM-85BV in the prevention of respiratory tract infections in children during 12 months. Chest 119:1742.
8. Linder A. 1988. Symptom scores as measures of the severity of rhinitis. Clin. Allergy 18:29.
9. Musso T., L. Calosso, M. Zucca, M. Millesimo, M. Puliti, S. Bulfone-Paus, C. Merlino, D. Savoia, R. Cavallo, A. Negro Ponzi and R. Badolato. 1998. Interleukin-15 activates proinflammatory and antimicrobial functions in polymorphonuclear cells. Infect. Immun. 66:2640.
10. Ebner C., U. Siemann, B. Bohle, M. Willheim, U. Wiedermann, S. Schenk, F. Klotz, H. Ebner, D. Kraft and O. Scheiner. 1997. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from Th2 to Th1 in T cell clones specific for Ph1 p 1, a major grass pollen allergen. Clin. Exp. Allergy 27:1007.
11. Czerkinsky C., F. Anjuere, J.R. McGhee, A. George-Chandy, J. Holmgren, M.P. Kieny, K. Fujiyashi, J.F. Mestecky, V. Pierrefite-Carle, C. Rask and J.B. Sun. 1999. Mucosal immunity and tolerance: relevance to vaccine development. Immunol. Rev. 170:197.
12. Simon D., S. Borelli, L.R. Braathen and H.U. Simon. 2002. Peripheral blood mononuclear cells from IgE- and non-IgE-associated allergic atopic eczema/dermatitis syndrome (AEDS) demonstrate increased capacity of generating interleukin-13 but differ in their potential of synthesizing interferon-γ. Allergy 57:431.
13. Husband A.J. 2002. Mucosal memory-maintenance and recruitment. Vet. Immunol. Immunopathol. 87:131.
14. Kyd J.M. and A.W. Cripps. 1999. Killed whole bacterial cells, a mucosal delivery system for the induction of immunity in the respiratory tract and middle ear: an overview. Vaccine 17:1775.
15. Lanzilli G., R. Falchetti, M. Tricarico, D. Ungheri and M.P. Fuggetta. 2005. In vitro effects of an immunostimulating bacterial lysate on human lymphocyte function. Int. J. Immunopathol. Pharmacol. 18:245.
16. Cavallo G.P., M. Elia, D. Giordano, C. Baldi and R. Cammarota. 2002. Decrease of specific and total IgE levels in allergic patients after BCG vaccination. Arch. Otolaryngol. Head Neck Surg. 128:1058.
17. Testa B., C. Mesolella, M.R. Mosti, M. Mesolella, D. Testa and G. Motta. 2001. Changes in serum interferon-y, interleukin-4, and interleukin-12 cytokine levels in anti-histamine type 2-treated allergic rhinitis patients. Laryngoscope 111:236.
18. Smart J.M. and A.S. Kemp. 2002. Increased Th1 and Th2 allergen-induced cytokine responses in children with atopic disease. Clin. Exp. Allergy 32:796.
19. Laan M.P., M.R.M. Baert, A.E.C.M. Vredendaal and H.F.J. Savelkoul. 1998. Differential mRNA expression and production of interleukin-4 and interferon-gamma in stimulated peripheral blood mononuclear cells of house-dust mite-allergic patients. Eur. Cytokine Netw. 9:75.
20. Jahreis A., P. Beckheinrich and U.F. Haustein. 2000. Effects of two novel cationic staphylococcal proteins (NP-tase and p70) and enterotoxin B on IgE synthesis and interleukin-4 and interferon-γ production in patients with atopic dermatitis. Br. J. Dermatol. 142:680.
21. Yang S.H., C.Y. Hong and C.L. Yu. 2001. Decreased serum IgE level, decreased IFN-g and IL-5 but increased IL-10 production, end suppressed cyclooxygenase 2 mRNA expression in patients with perennial allergic rhinitis after treatment with a new mixed formula of Chinese herbs. Int. Immunopharmacol. 1:1173.
22. + T cells from allergic individuals. J. Exp. Med. 178:2123.
23. MacDonald S.M., R.M. Naclerio and R.G. Hamilton. 1994. Cytokine measurements in patients receiving standard immunotherapy. J. Allergy Clin. Immunol. 93:230.
24. Tanaka A., Y. Ohashi, Y. Kakinoki and Y. Nakai. 1998. Immunotherapy suppresses both Th1 and Th2 responses by allergen stimulation, but suppression of the Th2 response is a more important mechanism related to the clinical efficacy of immunotherapy for perennial allergic rhinitis. Scand. J. Immunol. 48:201.
25. Lanzilli G., R. Falchetti, A. Cottarelli, A. Macchi, D. Ungheri and M.P. Fuggetta. 2006. In vivo effect of an immunostimulating bacterial lysate on human B lymphocytes. Int. J. Immunopathol. Pharmacol. (in press).
26. Klimek L., D. Dormann, E.R. Jarman, O. Cromwell, H. Riechelmann and A.B. Reske-Kunz. 1999. Short-term pre-seasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis. Clin. Exp. Allergy 29:1326.